We investigated the effect of n-6 polyunsaturated fatty acids (PUFAs) on prostaglandin (PG) production by the uterus. A mixed population of endometrial cells (epthelium and stroma) from late-gestation ewes were cultured in defined medium containing linoleic acid (LA, 18:2, n-6), -linolenic acid (GLA, 18:3, or arachidonic acid (AA, 20:4, in concentrations of 0 (control), 20 or 100 µM. After 45 h in test medium with or without added PUFAs, cells were challenged with control medium (CM), oxytocin (OT, 250 nM), lipopolysaccharide (LPS, 0·1 µg/ml) or dexamethasone (DEX, 5 µM) for 22 h in the continued presence of the same concentration of PUFA and the medium was collected for measurement of PGF 2 and PGE 2 . Supplementation with LA inhibited the production of PGF 2 but did not alter PGE 2 , whereas GLA and AA increased production of both PGs. All PUFA supplements thus increased the ratio of PGE 2 to PGF 2 (E:F ratio) two-to threefold. In control cells, OT and LPS challenges stimulated the production of PGF 2 and PGE 2 . In all challenge groups, the concentrations of PGF 2 in response to PUFAs followed the same patternLA<control<GLA<AA -but there were significant alterations in responsiveness as a result of PUFA treatment. In the cells supplemented with 100 µM AA, there was no further increase in PGF 2 output in the presence of OT or LPS and when 100 µM GLA was present neither LPS nor OT stimulated PGE 2 significantly. When LPS was given to AA-supplemented cells, the E:F ratio was increased. DEX did not change PGE 2 production in control or LA-treated cells, but the cells produced significantly less PGF 2 , so the E:F ratio was increased. In contrast, in GLA-and AA-treated cells, DEX reduced the production of both PGF 2 and PGE 2 , so the E:F ratio was unaltered. In summary, the study showed altered production of PGs in the presence of different PUFAs according to their position in the n-6 metabolic pathway. The type of PUFA present affected responsiveness to OT, LPS and DEX and also changed the ratio of PGE 2 to PGF 2 produced. The possible implications of this work are discussed in relation to the effect of diet on term and pre-term labour, which both require upregulation of the endometrial PG synthetic pathway.
Introduction
Cardiovascular disease is the principal cause of death among the human population of developed countries, with the saturated fat content of the diet identified as one of the major risk factors (Department of Health 1995) . This finding has promoted a trend to reduce dietary intakes of meat and dairy products in favour of a substantial increase in vegetable oils, which are high in n-6 polyunsaturated fatty acids (PUFAs), notably linoleic acid (LA, 18:2, . Oils containing -linolenic acid (GLA, 18:3, , such as primrose oil, are also promoted as health products, because of their potential anti-inflammatory and anti-proliferative properties (Fan & Chapkin 1998) . Dietary PUFAs provide energy and components for cell membranes. They also act as the precursors for a variety of signalling molecules and influence many fundamental cell processes. LA is an essential fatty acid, which is metabolised in the body to GLA, dihomo--linolenic acid (DGLA, 20:3, and arachidonic acid (AA, 20:4, by the position-specific 6 and 5 desaturase and coenzyme A (CoA)-dependent chain elongases (Sprecher 2000) . Cyclo-oxygenases (COX) catalyse conversion of DGLA and AA into 1-and 2-series prostaglandins (PGs) respectively.
In the n-6 PUFA metabolic pathway from LA to AA, there are two rate-limiting catalytic steps, 6 and 5 desaturases. The amount of LA converted to GLA is tiny and only a small fraction of GLA can be catalysed into AA (Fan & Chapkin 1998) . Supplementation with GLA bypasses the rate-limiting 6 desaturase and GLA is quickly elongated to DGLA by elongase. DGLA can in turn be converted into 1-series PGs, such as PGF 1 and PGE 1 . Supplementation with AA avoids the limitation of 5 desaturase and AA is directly converted to 2-series PGs, such as PGF 2 and PGE 2 , by COX enzymes (Lapetina 1982) . This suggests that supplementary PUFAs may alter the n-6 PUFA metabolic pathway and that the precise effects of PUFAs on PG production will depend on their position in the pathway.
Considerable attention has been paid to the effects of PUFA supplementation on carcinogenesis, because PGs have an important role in the regulation of tumour growth (Bishop-Bailey et al. 2002 , Dommels et al. 2002 . To date, relatively little information is available about the possible effects of increased n-6 PUFA concentrations on the production of PG in relation to reproductive processes (Abayasekara & Wathes 1999) . Previous studies have produced contradictory results, in that feeding dairy cows a diet high in LA caused either a decreased (Thatcher et al. 1994 , Cheng et al. 2001a or an increased (Robinson et al. 2002) production of 2-series PG by the uterine endometrium. Graham et al. (1994) found a reduced ability of the endometrium to produce PGF 2 and PGE 2 in women who had been taking a dietary supplement of GLA for 6 months.
Upregulation of the 2-series PGs, in particular PGE 2 and PGF 2 , is an essential component of parturition (Challis 2000) . In the ewe, activation of the fetal hypothalamic-pituitary-adrenal axis in late gestation leads to increased production of PGE 2 by the placenta and subsequent initiation of parturition (Thorburn 1991) . In phase 1 of labour, the increased cortisol output stimulates the conversion of androgen to oestrogen in the placenta, upregulates the expression of COX-2 and downregulates the production of PG dehydrogenase (PGDH), resulting in increased production of PGE 2 (Challis et al. 2002) . In phase 2 of labour, oxytocin (OT) receptors are upregulated in the intercotyledonary endometrium (Leung et al. 1999) and mediate increased release of PGF 2 in response to OT (Jenkin 1992) , resulting in uterine contractions and delivery (Whittle et al. 2001 , Challis et al. 2002 . Synthetic glucocorticoids such as dexamethesone (DEX) can mimic the endogenous increase in cortisol and induce parturition (Challis et al. 2002) . Pregnant women given exogenous corticosteroids to promote fetal maturation have an increased incidence of pre-term birth (Challis et al. 2002) . Intrauterine infection is another major risk factor in pre-term labour (Goncalves et al. 2002) . The bacterial endotoxin, lipopolysaccharide (LPS), increased the activities of phospholipase (PL) A 2 and COX-2 and inhibited PGDH (Lamont et al. 1990 , Flynn & Hoff 1995 , van Meir et al. 1997 . Administration of LPS to pregnant mice provoked premature delivery (Romero et al. 1991) .
The aim of the present study was, therefore, to compare the effects of LA, GLA and AA on the generation of PG by the ovine endometrium in late gestation. The influence of several agonists known to play an important part in natural or pre-term labour were also examined by testing the responsiveness of the cells to OT, LPS and DEX.
Materials and Methods
All reagents were from Sigma (Poole, Dorset, UK) or BDH Merck Ltd (Lutterworth, Leics, UK) unless otherwise stated. Solutions were sterilised by passage through a 0·20 µm filter (Nalge Nunc International, Rochester, NY, USA or Millipore Company, Bedford, MA, USA). All culture media used included 50 000 units/l penicillin and 50 mg/l streptomycin.
Cell isolation and culture
Gravid uteri were obtained on day 135 of gestation (term is approximately 145 days). Ewes were killed using an overdose of pentabarbitone and the reproductive tract was collected.
Endometrial cells were isolated and cultured under sterile conditions in a laminar flow hood, following methods described previously (Cheng et al. 2003) . From the intercotyledonary region of the uterus, maternal endometrium was separated, cut into strips and put into serum-free Dulbecco's minimal essential medium/F12 1:1 nutrient mix (DMEM/F12 medium, Gibco Life Technologies, Paisley, Strathclyde, UK) containing 1·125 g/l fatty-acid-free bovine serum albumin (BSA, Sigma) and 1·125 g/l sodium bicarbonate at pH 7·3. The strips were then chopped into 1 mm 3 cubes using a McIlwain mechanical tissue chopper (McIlwain Laboratory Engineering, Guilford, Surry, UK). Two aliquots of 20 g chopped tissue were placed into two falcon vials and mixed with 30 ml digestive solution. This contained 0·05% trypsin III (Roche, Diagnostic GmbH, Mannheim, Germany), 0·05% collagenase II (Roche) and 0·1% BSA (Sigma) in Hank's Balanced Saline (HBS, Sigma). After incubation for 2 h at 37 C with shaking, the suspensions were filtered through a 100 µm mesh. The filtrates were pooled into a 50 ml falcon vial and re-suspended with washing medium [HBS containing 10% (v/v) fetal calf serum (FCS, Sigma) and 3 µg/ml trypsin inhibitor (Sigma)]. The vial was then centrifuged at 100 g and 4 C for 10 min. The supernatant was removed and the pellet re-suspended with washing medium. After two repetitions of the above washing procedures, the cell pellets containing mixed epithelial and stromal cells were re-suspended in DMEM/F12 medium containing 10% FCS to a concentration of 0·5 10 6 cells/ml. This cell suspension was plated (2 ml/well) into 24-well IWAKI microplates (Scitech DIV, Asahi Techno Glass, Japan). Cells were cultured in a humidified incubator at 39 C with 5% CO 2 . Culture medium was changed every 48 h for 7-8 days to allow the cells to grow to confluence.
PUFA supplementation and cell challenge
LA, GLA and AA (Sigma) were dissolved in 100% ethanol to a concentration of 100 mM. Further dilution to 10 mM was made in dilution medium (serum-free DMEM/F12 containing 0·1125% fatty-acid-free BSA as a carrier). OT (Sigma) was dissolved in 0·01 M acetic acid at 5 mM then further diluted to 500 µM in dilution medium. LPS from Escherichia coli 026.B6 (Sigma) was dissolved in distilled water at 500 µg/ml then diluted to 50 µg/ml in dilution medium. DEX (Sigma) was dissolved in 100% ethanol to 20 mM, then diluted to 2 mM in dilution medium.
Before PUFA supplementation, confluent cells were incubated with 2 ml serum-free test medium containing 0·1125% BSA and ITS (0·5 µg/ml insulin, 0·5 µg/ml transferrin and 0·5 ng/ml selenium; Sigma) for 3 h to remove any fatty acids present in the FCS. The cells were then grown in 2 ml PUFA-supplemented test medium for 45 h. The PUFA treatments were LA, GLA or AA at 0 (control), 20 or 100 µM, formulated in the test medium. After this initial culture period, cells cultured in 0 or 100 µM PUFA were challenged with control medium (CM), OT (250 nM), LPS (0·1 µg/ml) or DEX (5 µM) in 1 ml of PUFA-supplemented test medium for 22 h. The doses of PUFA were selected to fall within the effective range, after preliminary work using a wider dose-response curve. The maximum ethanol concentration in the incubation medium was always less than 0·05%. Spent medium was stored at 20 C until analysis for PGs. There were four replicate wells per treatment for each ewe, and all treatments were repeated in cells isolated from at least three separate ewes.
PG RIA
PGE 2 and PGF 2 in the spent medium were quantified using charcoal-dextran-coated RIA methods as described previously (Cheng et al. 2001a) . The samples were diluted ( 20-500) in 0·05 M Tris buffer containing 0·1% gelatin and 0·01% sodium azide. At this dilution, the presence of the control medium had negligible effect on the RIAs (<1%), so no extraction of the samples was required. The tritiated tracers of PGE 2 ([5, 6, 8, 11, 12, 14, 15 (n)- 3 H]-PGE 2 ) and PGF 2 ([5, 6, 8, 9, 11, 12, 14, 15 (n)- 3 H]-PGF 2 ) were purchased from Amersham International plc (Amersham, Bucks, UK). The standards of PGE 2 and PGF 2 were supplied by Sigma. The antisera to these two PGs were a kind gift from Dr N L Poyser (University of Edinburgh, Edinburgh, UK) (Poyser 1987) . Their cross-reactivities were as follows: PGF 2 antiserum, 34% with PGF 1 and 25% with PGF 3 ; PGE 2 antiserum, 23% with PGE 1 and 15% with PGE 3 . The limit of detection was 2 pg/tube for PGE 2 and 1 pg/tube for PGF 2 . The intra-and interassay coefficients of variation were 3·5% and 6·3% for PGE 2 (n=6), and 4·1% and 9·6% for PGF 2 (n=6) respectively.
Statistical analysis
The data are expressed as means S.E. unless otherwise stated. Analysis of variance (ANOVA) was carried out using a mixed-procedure built-in SAS software package (Version 8.0, SAS Institute Inc., Cary, NC, USA). The differences between PUFA treatments, challenges and their interactions were taken as the fixed effects and sheep as the random effect. When a significant difference (P<0·05) was achieved, the least square means based on Fisher's LSD for multiple comparisons were calculated to test the differences between the fixed effects.
Results

Effects of n-6 PUFAs on PG production in non-challenged cells
There were significant differences between the PUFA treatments with respect to both PGF 2 and PGE 2 concentrations (Fig. 1) . Compared with control, supplementation with LA dose-dependently inhibited the generation of PGF 2 (P<0·05-0·01), whereas GLA and AA increased its production by up to 14-fold (P<0·001). There were no significant differences in PGF 2 concentrations between 20 µM and 100 µM GLA or AA supplementation. AA at 20 and 100 µM stimulated significantly greater generation of PGF 2 than did GLA at the same concentrations (P<0·05-0·01).
LA supplementation did not alter the production of PGE 2 significantly, although the PGE 2 concentration was slightly lower in cells treated with 100 µM LA. Supplementation with GLA increased PGE 2 production by up to 15-fold (P<0·01), supplementation with 100 µM producing significantly greater generation of PGE 2 than supplementation with 20 µM (P<0·01). In the cells supplemented with 20 and 100 µM AA, the PGE 2 concentrations were up to 40 times greater than those in control cells (P<0·001). Compared with the GLAsupplemented cells, those supplemented with AA generated significantly more PGE 2 at the same PUFA concentrations (P<0·01).
In the cells cultured with PUFA-free medium, similar amounts of PGF 2 and PGE 2 were produced, indicated by a PGE 2 to PGF 2 (E:F) ratio of 1·0 0·11 (Fig. 1) . PUFA supplementation alone (LA, GLA and AA) significantly increased this ratio, two-to threefold.
Effect of challenges on PG production
Cells stimulated with OT in PUFA-free medium increased their release of both PGF 2 and PGE 2 about twofold in equal proportion, resulting in an E:F ratio of 1·2 0·18 (Fig. 2) . This response was attenuated by LA. The cells produced more prostaglandins in the presence of both GLA and AA, but the further response of PGF 2 to OT was no longer significant in cells cultured with AA and the response of PGE 2 to GLA was likewise lost in the presence of GLA. There was a trend for all three n-6 PUFAs tested to increase the E:F ratio, but this was only significant for GLA (2·8 0·27; Fig. 2 ). OT treatment did not alter the ratio.
Cells stimulated with LPS in PUFA-free medium also increased release of both prostaglandins and, again, the E:F ratio remained unaltered, at about 1 (0·9 0·11; Fig. 3 ). The production of PGF 2 in response to LPS was decreased in the presence of LA. In the presence of AA, cells could no longer respond to LPS by further production of PGF 2 . The response of PGE 2 to LPS was likewise lost in the presence of GLA. There was a progressive increase in the E:F ratio from control medium<LA<GLA<AA.
The combination of LPS in the presence of AA produced a further significant increase in the E:F ratio, to 3·5 0·47 (Fig. 3) .
In cells treated with DEX in PUFA-free medium or with LA, PGF 2 was reduced, whereas PGE 2 was unaltered, resulting in a significant increase in the E:F ratio, to more than 3 (Fig. 4) . In the presence of GLA and AA, DEX reduced the production of both PGF 2 and PGE 2 , so the E:F ratio was no longer altered.
Discussion
In this study we investigated the effect of n-6 PUFA supplementation on the production of prostaglandin by ovine endometrial cells from late-gestation ewes, and examined how PUFA treatment affected the responsiveness to a variety of treatments known to influence Figure 1 The effect of n-6 PUFA supplementation on the production of PGs by ovine endometrial cells. Cells were supplemented with no PUFA (0, CONT) or 20 or 100 M LA, GLA or AA. There were three ewes per treatment and four replicates per ewe. Values are expressed as means S.E.M. over a 22 h culture period. Data were analysed by split ANOVA. The line on the bottom graph marks an E:F ratio of 1, indicating that equivalent amounts of each PG were being produced. Different letters indicate significant difference at P<0·05-0·0001 (a<b<c<d<e<f<g).
Figure 2 Effects of n-6
PUFAs on the production of PGs by ovine endometrial cells after OT challenges. Confluent cells were preincubated for 45 h in either control (PUFA-free) medium or with 100 M LA, GLA or AA. Cells were then treated with control medium (M) or with 250 nM OT () for 22 h. The line on the bottom graph marks an E:F ratio of 1, indicating that equivalent amounts of each PG were being produced. There were three ewes per treatment and four replicates per ewe. Values are expressed as means S.E.M. Data were analysed by split ANOVA. Significant differences attributable to OT treatment: *P<0·05, **P<0·01; significant differences attributable to PUFA treatment: a<b<c<d, P<0·05-0·0001.
prostaglandin synthesis. Upregulation of endometrial PG production is an essential component of parturition. PGE 2 is required for fetal maturation, membrane rupture and cervical ripening, whereas PGF 2 acts on the myometrium to induce uterine contractions (Whittle et al. 2001) . The concentrations of PUFAs tested (20-100 µmol) were in the same range as those we have shown to be present in the intercotyledonary endometrium of late-gestation ewes. These were 188 13, 11 1 and 412 37 nmol/g respectively for LA, GLA and AA in the phosphatidylcholine membrane fraction and 68 11, 22 2 and 398 31 nmol/g respectively for LA, GLA and AA in the phosphatidylethanolamine membrane fraction (M Elmes, P Tew, SE Kirkup, Z Cheng, GC Burdge, DRE Abayasekara, PC Calder, MA Hanson & DC Wathes, unpublished observations). We have shown here: (1) altered production of PGs in the presence of different n-6 PUFAs; (2) that the type of PUFA present can affect responsiveness to OT, LPS and DEX; and (3) that the ratio of PGE 2 to PGF 2 produced by the endometrium can also be changed by PUFA supplementation.
The addition of LA to the endometrial cells decreased PGF 2 but did not affect the amount of PGE 2 produced. In contrast, GLA and AA considerably stimulated production of both PGs. The stimulatory effect of GLA and AA was as expected, given their respective positions in the n-6 metabolic pathway and that AA can be directly converted to 2-series prostaglandins. The cells supplemented with AA produced almost twice the amount of PGE 2 and PGF 2 as those supplemented with GLA. In vivo, GLA can be converted to DGLA by the elongase enzyme and this is further converted to AA by 5 desaturase. If that were happening here, it is likely that some of the DGLA produced would have given rise to 1-series PGs, which would only partially cross react with our antisera. We have evidence that this does occur after supplementation of Figure 3 Effects of n-6 PUFAs on the production of PGs by ovine endometrial cells after LPS challenges. Confluent cells were preincubated for 45 h in either control (PUFA-free) medium or with 100 M LA, GLA or AA. Cells were then treated with control medium (M) or with 0·1 g/ml LPS () for 22 h. The line on the bottom graph marks an E:F ratio of 1, indicating that equivalent amounts of each PG were being produced. There were three ewes per treatment and four replicates per ewe. Values are expressed as means S.E.M. Data were analysed by split ANOVA. Significant differences attributable to LPS treatment: *P<0·05, **P<0·01; significant differences attributable to PUFA treatment: a<b<c, P<0·05-0·001.
Figure 4 Effects of n-6
PUFAs on the production of PGs by ovine endometrial cells after DEX challenges. Confluent cells were preincubated for 45 h in either control (PUFA-free) medium or with 100 M LA, GLA or AA. Cells were then treated with control medium (M) or with 5 M DEX () for 22 h. The line on the bottom graph marks an E:F ratio of 1, indicating that equivalent amounts of each PG were being produced. There were three ewes per treatment and four replicates per ewe. Values are expressed as means S.E.M. Data were analysed by split ANOVA. Significant differences attributable to DEX treatment: *P<0·05, **P<0·01; significant differences attributable to PUFA treatment: a<b<c<d, P<0·05-0·0001.
GLA to cultured endometrial cells from non-pregnant ewes or amnion cells, as assessed by separating PG fractions on HPLC (Z Cheng, S E Kirkup, D C Wathes & D R E Abayasekara, unpublished observations), so the reported production of PG after supplementation with GLA is probably an underestimate. In these studies of non-pregnant endometrial cells, however, LA did not increase the production of PGF 1 , suggesting that 6 desaturase is not present in the cultures. The inhibitory effect of LA was in agreement with our previous work using uterine endometrial cells isolated from non-pregnant cows and ewes (Cheng et al. 2001a,b) . LA has variously been reported to stimulate or inhibit the production of PG in different studies. In rat gastric mucosal cells, for example, supplementation with LA stimulated AA and PGE 2 production (Nakaya et al. 2001) . Similarly, the enhancement of tumour growth by LA has been reported in a number of studies and the mechanisms were attributed to the increased production of PGE 2 catalysed from the increased accumulation of AA by COX-2 (Connolly et al. 1996 , Dommels et al. 2002 . In contrast, Thatcher et al. (1994) reported that LA inhibited the production of PG by the bovine endometrium. A possible reason for the decreased PG production may be that accumulation of excess LA competes with AA both for incorporation to the cell membrane and for COX. Although AA is the preferred substrate for COX-1 and -2, both isoforms can oxygenate a variety of n-3 and n-6 18-22 carbon PUFAs (Laneuville et al. 1995 , Larsen et al. 1996 , Rowlinson et al. 1999 .
In the cells cultured in PUFA-free medium, similar amounts of PGE 2 and PGF 2 were produced, but supplementation with all three PUFAs tested increased the E:F ratio by about two-to threefold. In the presence of LA, PGE 2 was unchanged, whereas the production of PGF 2 was inhibited. In contrast, when GLA or AA were present there was a greater increase in PGE 2 than in PGF 2 . The reasons for this are not clear. In the present study, the dispersed endometrial tissue contained a mixed population of epithelial and stromal cells, thus allowing the potential for paracrine interactions. In the non-pregnant ewe, PGF 2 is principally produced by the epithelial cells and PGE 2 by the stromal cells (Cherny & Findlay 1990) . Different cell types may differ in their capability for PUFA incorporation and metabolism because of their differences in enzyme systems, and they may also use different AA pools for the production of PG. In the late-gestation ewe, however, in situ hybridisation and immunocytochemical studies show that COX-2 is localised exclusively to the uterine epithelial cells and that COX-1 mRNA is not detectable , suggesting that it is mainly the epithelial cells that are involved in PG production at this stage. In the PG metabolic pathway, COX-1 and COX-2 catalyse AA into the intermediate PGH 2 that is subsequently converted into one of a variety of bioactive PGs by specific PG isomerases/synthases. The amount and ratio of PGF 2 and PGE 2 produced are therefore dependent on both COX activity and the specific PGF and PGE isomerase/synthase. It is possible that PUFA supplementation may enhance the activity of PGEs. A previous study showed that dispersed bovine placental cells were able to convert up to 19% of added 3 H-PGF 2 into PGE 2 , whereas the reverse conversion of PGE 2 to PGF 2 was minimal (<4%) (Gross & Williams 1988) . In that study, the identity of the PGE 2 produced was confirmed by gas chromatography/mass spectrometry and the results implied the presence of the 9-hydroxy-PG dehydrogenase enzyme in the bovine placenta. This raises another possibility, that PUFA supplementation may accelerate the conversion process, although this would require testing in this system.
In the cells cultured with PUFA-free medium, OT and LPS challenge both significantly increased the production of PGE 2 and PGF 2 . This is in accord with many previous studies showing that both OT and LPS can stimulate cPLA 2 and COX-2 expression to increase PG output (Lee & Silvia 1994 , Flynn & Hoff 1995 , Asselin et al. 1997 . However, neither OT nor LPS increased PG output to the same extent as was achieved by the addition of either GLA or AA alone. Similar stimulatory effects of OT and LPS were seen in the added presence of PUFAs; however, some interesting interactions were observed. OT and LPS were unable to stimulate PGF 2 output further in the presence of AA. GLA similarly prevented the stimulatory effect of both OT and LPS on the production of PGE 2 . The combination of AA with LPS altered the E:F ratio in favour of PGE 2 . This indicates that n-6 PUFAs can not only alter the basal production of uterine PGs, but also the responsiveness of the uterus to these challenges. Several mechanisms may be involved. OT and LPS increase PG output via upregulation of cPLA 2 and COX-2 expression. In the presence of a high concentration of precursor, the availability of either of these enzymes may become rate limiting. Studies involving activation of the OT receptor in preformed liposomes showed a strong dependence of OT receptor function on both the amount of cholesterol present within the membrane and the specific structure of the cholesterol molecule (Fahrenholz et al. 1995) . LPS utilizes the Toll-like receptor 4 (Tlr4) to induce the transcription and expression of COX-2 (Poltorak et al. 1998 , Rhee & Hwang 2000 , and PUFAs, including LA and AA, inhibited the induction of LPS on COX-2 expression via interruption of the Tlr4 signalling pathway (Lee et al. 2001) . It is likely that membrane characteristics are altered by their PUFA content, and this may in turn influence signalling pathways through changes in receptor binding characteristics or downstream activation. There could well be independent effects of PUFAs on the OT and LPS signalling pathways.
With regard to the inhibitory effect of the DEX challenge on the production of PGF 2 in PUFA-free cells, glucocorticoids have been classified as COX-2 inhibitors in the anti-inflammatory pathway (DeWitt & Meade 1993 , Evett et al. 1993 . In amnion cells, Blumenstein et al. (2000) also demonstrated that DEX could inhibit the production of PGE 2 . It has been well documented, however, that parturition in the ewe is initiated by the fetus after activation of the hypothalamic-pituitary-adrenal axis, and that increased intrauterine PG output is caused by the increased cortisol output (Whittle et al. 2001) . Previous studies showed that synthetic glucocorticoids, such as DEX and -methasone, stimulated intrauterine COX-2 expression and inhibited PGDH in intrauterine tissues (Zakar et al. 1995 , Challis et al. 2002 . COX-2 has a glucocorticoid response element in its promoter region (Tazawa et al. 1994 ) and glucocorticoids may also mediate non-genomic effects through a G-protein-coupled membrane-associated receptor (McKay & Cidlowski 1999) . Whittle et al. (2001) reviewed the different mechanisms whereby glucocorticoids might alter COX-2 expression. A wide variety of factors can clearly influence the result, including cell type, dose, time-course, whether the cells are dividing and other components of the endocrine background such as the presence of oestrogen and inflammatory interleukins. They suggested that the pro-inflammatory effects occurred when COX-2 expression was basal, whereas the anti-inflammatory effects were apparent only when the expression of COX-2 had already been upregulated. In our study, an inhibitory effect of DEX on PGE 2 production was seen only in the additional presence of GLA or AA, when PG production was increased, thus shifting the ratio in favour of more PGF 2 . This adds another dimension to an already complex issue. In the context of labour, such a shift could potentially promote uterine contractility.
In conclusion, supplementation of n-6 PUFAs in vitro can alter both the amount and the proportion of the basal production of uterine PGs and the responsiveness of the uterus to OT, LPS and DEX. These results suggest that dietary differences in n-6 PUFAs may affect both the initiation and progression of parturition. Within the UK, 2·5% of the female population consume more than 20 g n-6 PUFA per day (Office of Population Censuses and Surveys 1990), mostly as LA derived from plant oils and soya. This is nearly 10 times the amount needed for normal bodily function (Kinsella et al. 1990 ). GLA-rich products, such as evening primrose oil, blackcurrant oil and borage oil, are widely considered to benefit human health (Fan & Chapkin 1998) . Decreased responsiveness of PGE 2 production to LPS challenge caused by GLA supplementation might potentially assist the prevention of pre-term labour. The shift in the E:F ratio in response to DEX in the presence of AA suggests that diets producing high tissue concentrations of AA may alter inflammatory responses. In order to test these interesting possibilities, further studies are required to determine how different dietary regimes alter PG production in vivo.
